PRECISE_T2D: Precision Dosing of Metformin in Youth With T2D
Study Details
Study Description
Brief Summary
The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Early Phase 1 |
Detailed Description
Based on the investigators previous studies of young people who take metformin, the study team found that young people's bodies process metformin faster than older people and young people may need higher doses of metformin for the best treatment outcomes. The purpose of this study is to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental 1350mg metformin twice per day |
Drug: Metformin
Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
|
| Active Comparator: Active Comparator 1000mg metformin twice per day |
Drug: Metformin
Participants will receive either 2700mg of metformin/day (1350mg twice a day) or 2000mg of metformin/day (1000mg twice a day, standard of care). The study intervention will be blinded to the participants as they will receive the same number of pills (4 pills of the same size) regardless of whether they are in the intervention arm or control arm .
|
Outcome Measures
Primary Outcome Measures
- Acceptability of Higher Metformin Dose measured with the Acceptability of Intervention Measure (AIM) [Measured at 3 months]
The perception that a higher dose of Metformin is agreeable or satisfactory measured with the 4-item Acceptability of Intervention Measure (AIM). A 4-item measure of perceived intervention acceptability. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean. The greater the score, the better the acceptability.
- Feasibility of Higher Metformin Dose measured with the Feasibility of Intervention Measure (FIM) [Measured at 3 months]
The extent to which a higher dose Metformin study can be successfully carried out measured with 4-item Feasibility of Intervention Measure (FIM). A 4-item instrument to assess perceived intervention feasibility. Items are measured on a 5-point Likert scale (Completely Disagree-Completely Agree). Score is calculated mean. The greater the score, the better the feasibility.
Secondary Outcome Measures
- Glycemic Change [Baseline (0) to 3 months]
Change in serum HbA1C at 3 months adjusted for the baseline value youth with T2D on higher dose of metformin compared to standard dose
- Time in target glucose range [Baseline (0) to 3 months]
Time spent in target glucose range of 70 to 180 mg/dL
- Time above high glucose range [Baseline (0) to 3 months]
Percent of readings and time >250 mg/dL
- Time above glucose range [Baseline (0) to 3 months]
Percent of readings and time 181-250 mg/dL
- Time in glucose range [Baseline (0) to 3 months]
Percent of readings and time 70-180 mg/dL
- Time below glucose range [Baseline (0) to 3 months]
Percent of readings and time 54-69 mg/dL
- Time below low glucose range [Baseline (0) to 3 months]
Percent of readings and time <54 mg/dl
- Glucose management indicator [Baseline (0) to 3 months]
Continuous glucose monitoring (CGM) metric that indicates average blood glucose. Glucose Management Indicator (GMI) approximates the laboratory A1C level expected based on average glucose measured using CGM values. Average glucose is derived from 14 or more days of CGM readings.
- Co-efficient of variation of glucose [Baseline (0) to 3 months]
CGM metric that measures variability in CGM values
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age 8-21 years
-
Provider diagnosis of T2D
-
Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose)
-
≥ 1 month from T2D diagnosis
-
Taking regular metformin (not extended-release formula)
-
Ability to wear CGM for a total of 6 weeks while in the study.
-
English or Spanish speakers.
-
Willing to abide by recommendations and study procedures.
-
Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF.
-
Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Exclusion Criteria:
-
Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8).
-
Known history of ongoing renal or hepatic disease.
-
Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | UCSF Madison Clinic for Pediatric Diabetes | San Francisco | California | United States | 94158 |
Sponsors and Collaborators
- University of California, San Francisco
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
- Principal Investigator: Shylaja Srinivasan, MD, University of California, San Francisco
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 23-39745
- K23DK120932